November 16, 2026 1:09 PM 2 min read
CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds
by Vandana Singh Benzinga Staff Writer
Follow
CGONCG Oncology Inc
$86.6616.5%
Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
Reveal Full Score Edge Rankings
Momentum93.08
GrowthN/A
QualityN/A
ValueN/A
Price Trend
ShortMediumLongOverview CG Oncology Inc. (NASDAQ:CGON) on Monday announced positive topline results from its Phase 3 PIVOT-006 trial, which Arthur Kuan, chairman, president, and CEO of CG Oncology, called a defining milestone for the company.
Kuan stated that the data position cretostimogene grenadenorepvec as the first and only therapeutic candidate to show a significant recurrence benefit in a pivotal Phase 3 study for intermediate-risk and high-grade Ta NMIBC, prompting the company to advance two BLA filings in 2027.
PIVOT-006 Trial Delivers 68% Recurrence Risk Reduction
The registrational PIVOT-006 study…